

An *in vivo* model of functional and vascularized human brain organoids

Abed AlFatah Mansour¹ , J Tiago Gonçalves^{1,4}, Cooper W Bloyd¹, Hao Li², Sarah Fernandes^{1,3}, Daphne Quang¹, Stephen Johnston¹, Sarah L Parylak¹, Xin Jin² & Fred H Gage¹

Differentiation of human pluripotent stem cells to small brain-like structures known as brain organoids offers an unprecedented opportunity to model human brain development and disease. To provide a vascularized and functional *in vivo* model of brain organoids, we established a method for transplanting human brain organoids into the adult mouse brain. Organoid grafts showed progressive neuronal differentiation and maturation, gliogenesis, integration of microglia, and growth of axons to multiple regions of the host brain. *In vivo* two-photon imaging demonstrated functional neuronal networks and blood vessels in the grafts. Finally, *in vivo* extracellular recording combined with optogenetics revealed intragraft neuronal activity and suggested graft-to-host functional synaptic connectivity. This combination of human neural organoids and an *in vivo* physiological environment in the animal brain may facilitate disease modeling under physiological conditions.

The development of adequate model systems to study the human brain in health and disease has proved challenging. Animal models, particularly rodents, and cell culture systems, such as those using human pluripotent stem cell (hPSC)-derived neural lineages¹, have provided tremendous insights into the development, function, and dysfunction of the human brain, but do not capture its full complexity^{2,3}. Three-dimensional (3D) neural tissues generated from hPSCs, termed brain organoids, have enormous potential for investigating aspects of human brain development and mental disorders^{4–11}. Brain organoids contain multiple cell types, have neuronal functionality *in vitro* that recapitulates some features of the development and maturation of complex neuronal tissue, and are more representative of *in vivo* physiology than two-dimensional cell cultures. While brain organoids have been successfully applied to study both human brain development and complex human diseases, limitations that preclude their broader application remain^{8,12–16}.

Current brain organoid systems lack the microenvironment, neuronal circuits, vascular circulation, and immune system that exist *in vivo*. Vascularization is particularly necessary for oxygen penetration, nutrient supply, and efficient neural progenitor differentiation^{17,18}. The lack of oxygen penetration renders the center of the organoid necrotic, which can interfere with its normal development and potential neuronal migration routes¹⁹. Integrating a vascular structure that allows adequate delivery of oxygen and nutrients is necessary to generate large organoids that are not limited in size by diffusion. Although co-cultures with vascular cells or tissue engineering may be capable of forming tubular networks in organoids and other 3D structures^{18,20}, the issues of nutrient supply and authentic blood microenvironment remain. Thus, an alternative approach may be engraftment into an animal host. While such engraftment has been successful for a wide

variety of solid tissues and for both normal and cancer organoids^{21–30}, to our knowledge, such an *in vivo* model system for vascularized human brain organoids has not yet been reported.

Here, we developed an efficient *in vivo* engraftment model of hPSC-derived brain organoids within a physiological tissue environment. The grafted organoids readily integrated into the mouse brain, exhibited progressive neuronal temporal differentiation patterns, developed a functional vasculature system, and displayed unprecedented axonal outgrowth to generate mature and functional human brain tissues *in vivo* that responded to physiological stimuli triggered by anesthesia. Finally, we used optogenetics to show functional synaptic connectivity between grafted organoids and the host brain.

RESULTS

Intracerebral grafting of brain organoids

Intracerebral implantation in rodents supports the long-term survival and vascularization of fetal and adult mouse tissue^{21,31,32}. Therefore, we hypothesized that intracerebral implantation of cerebral organoids could create a permissive environment for their development and long-term survival. We first transduced human embryonic stem cells (hESCs) with a lentivirus vector encoding EGFP to generate a GFP hESC line. GFP⁺ cerebral organoids were generated as described previously (**Fig. 1a** and **Supplementary Fig. 1a,b**)^{8,33}. Organoids were grown in culture for 40–50 d, unless stated otherwise, before intracerebral implantation into a cavity made in the retrosplenial cortex of NOD-SCID (nonobese diabetic- severe combined immunodeficient) (*Prkdc*^{scid})-immunodeficient mice (**Fig. 1a**). Only organoids that passed the quality criteria described previously³³—clearing of embryoid body borders, formation of radially organized neuroepithelium before Matrigel embedding, and outgrowth and development of

¹Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, California, USA. ²Molecular Neurobiology Laboratory, The Salk Institute for Biological Studies, La Jolla, California, USA. ³Department of Biology, San Diego State University, San Diego, California, USA. ⁴Present address: Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, New York, USA. Correspondence should be addressed to F.H.G. (gage@salk.edu).

Received 20 June 2017; accepted 23 March 2018; published online 16 April 2018; doi:[10.1038/nbt.4127](https://doi.org/10.1038/nbt.4127)

defined buds in Matrigel without massive cyst formation or premature differentiation—were selected for implantation. In addition, we confirmed the generation of polarized, radially organized, ventricular zone-like regions (VZ-L), and dorsal forebrain identity in the organoids (**Supplementary Fig. 1c,d**).

Approximately 92% of grafted animals survived beyond 180 d (**Fig. 1c**). To test organoid graft survival, we examined GFP expression in the whole-mount brain after dissection. At 0.5–3 months post-implantation (PI), we observed robust integration and survival of the graft (80% ± 4%, $n = 28$ mice), with GFP⁺ processes extruding from the graft into the recipient brain (**Fig. 1b,d** and **Supplementary Fig. 2**). Only brains with clearly identifiable grafts were subsequently analyzed.

Organoid grafts exhibit progressive differentiation

To examine the differentiation potential of grafted organoids, we analyzed mouse brains at 0.5 to ~8 months. Human cells were first identified based on their expression of GFP, human nuclear antigen (hNuclei), and anti-human mitochondria antibody. At 14 and 90 d post-implantation (dpi), grafts exhibited robust integration and survival and were distributed throughout most of the implantation cavity (**Fig. 1d** and **Supplementary Fig. 2a,b**). A hallmark of cerebral organoids is the relatively dominant formation of forebrain identity, with well-defined neuroepithelial ventricular zones and cortical-like neuronal layers^{8,12} (**Supplementary Fig. 1c,d**). At 14 dpi, grafts showed segregation of well-defined SOX2⁺ VZ-L regions with typical radial morphology (**Fig. 1d,e** and **Fig. 2a**). The dorsal marker PAX6 was expressed in radial glia progenitors in the VZ-L regions, and CTIP2, a marker of an early-born deep neuronal cortical layer, was expressed in the cortical plate-like area (**Fig. 1e**). The combination of PAX6 and CTIP2 expression domains in the graft indicates their dorso-cortical identity. These results suggested that the regional and morphological identities of grafted organoids were preserved *in vivo*.

At their early developmental stage in culture, cerebral organoids consist of both neural progenitor cells (NPCs) and mature neuronal cells; at later stages NPCs undergo neurogenesis and mature to neurons^{8,12,13,33}. To examine whether similar progressive maturation occurred over time *in vivo*, we used the NPC marker SOX2 and the mature neuronal markers NeuN, MAP2, and SMI312. By 14 dpi, grafted organoids expressed SOX2 and NeuN, with relatively low presence of SMI312⁺ regions (**Fig. 2a**). At 50 dpi and 90 dpi, NeuN⁺ cells were enriched at the expense of SOX2, and prominent expression of the neuronal markers SMI312 and MAP2 was observed (**Fig. 2a,b** and **Supplementary Fig. 3b–d**). Organoid grafts survived up to 233 dpi, the latest time point tested in our study, and showed persistent expression of NeuN and SOX2 (**Supplementary Fig. 3e,f**). Comparison of differentiation dynamics of grafted organoids and nearly stage-matched cerebral organoids cultured *in vitro* revealed relatively higher numbers of NeuN⁺ cells at 50 dpi compared to 102-day *in vitro* organoids (41.76% ± 1.817; 10.94% ± 1.346, respectively), with no significant differences at earlier stages (**Fig. 2c**), suggesting that the *in vivo* environment enhanced cellular maturation and/or survival of organoids.

We next examined the level of gliogenesis within organoid grafts. Consistent with previous reports, we rarely observed the mature astrocyte marker GFAP in cultured organoids before the engraftment stage^{8,12,13,34} (**Supplementary Fig. 3a**). In grafted organoids, there were few human-specific GFAP⁺ cells at 14 dpi and a substantial increase at later time points (**Fig. 2d**). Glial astrocyte identity was confirmed by staining for S100 β (**Supplementary Fig. 3b**). At 50, 90, and 233 dpi, the majority of SOX2⁺ cells were not organized




Figure 1 Intracerebral grafting of brain organoids into mouse brain.

(a) Illustration of the experimental procedure for generation of GFP⁺ organoids from hESCs and intracerebral implantation into immunodeficient mouse brain. (b) Whole-mount dorsal view image of mouse brain grafted with a GFP⁺ cerebral organoid and harvested at 50 dpi; the graft is outlined in white. Right, magnified graft displaying neurite outgrowth from the organoid toward the host brain (arrowheads). (c) Kaplan–Meier survival curve for overall survival of mice after engraftment with brain organoids. (91.8% survival beyond 180 dpi, $n = 61$ mice from ten experiments). (d) GFP⁺ organoids were grafted into mouse brain and harvested at the indicated dpi. Coronal sections were analyzed using immunofluorescence and confocal microscopy. Immunofluorescence staining for GFP and human nuclear antigen (hNuclei), demonstrates that the implant survived well and distributed throughout the lesion cavity at 14 dpi. Left image shows confocal stitched tile scan; image was vertically inverted. White solid lines indicate apical/ventricular surface. Dotted white line indicates the radial glia VZ-L regions. Yellow lines indicate the graft-host border. (e) Graft immunostained for GFP, dorsal telencephalic progenitor marker PAX6 and the deep-layer subcortical neuron marker CTIP2. Radially organized cells (arrowhead, left panel) represent the PAX6⁺ VZ-L region (dotted white lines). $n = 4$ animals in b, and $n = 3$ animals in d,e. Nuclei were counterstained with DAPI. Scale bars: 1 mm in b, 100 μ m in d, and 20 μ m in e.

in tight, regionally restricted expression domains resembling stem cell niches, as observed at 14 dpi and in cultured organoids (**Fig. 2a**, **Supplementary Fig. 1d** and **3c,e**), but were sparsely distributed, raising the possibility that these were SOX2-expressing astrocytes³⁵ rather than NPCs. Co-localization of SOX2 and GFAP expression (**Supplementary Fig. 3b**) suggested an astrocyte fate. Furthermore, OLIG2 staining at middle and late stages revealed the presence of oligodendrocytes in the grafts (**Fig. 2e** and **Supplementary Fig. 3g**). However, when staining for myelin basic protein (MBP), we did not detect signs of myelination.

Immunostaining for the presynaptic marker Synapsin I and the postsynaptic marker PSD95 showed not only intragraft punctate staining of these markers, but also multiple Synapsin and PSD95 colocalized puncta, suggesting synaptic connectivity in the grafts (**Fig. 2g**). Immunostaining for the microglia marker Iba1 revealed abundant migration of Iba⁺ cells from the host throughout the graft at 90 and 233 dpi with typical ramified morphology (**Fig. 2f** and **Supplementary Fig. 3g**).




Figure 2 Survival and differentiation of grafted organoids. Organoids were grafted and harvested at the indicated dpi, coronal sections were analyzed using immunofluorescence and confocal microscopy. **(a)** Double immunofluorescence staining for SOX2 and NeuN (left), and GFP and SMI312 (right). At 14 dpi, the graft expresses both the NPCs marker SOX2 and the mature neuronal marker NeuN but shows low numbers of SMI312-positive processes. At 50 dpi, the graft retains a lower expression domain of SOX2, NeuN⁺ cells, and the SMI312-positive area increase. White solid lines indicate the apical/ventricular surface. Dotted white lines indicate the radial glia VZ-L regions. Yellow lines indicate the graft-host border. **(b)** Quantification of the percentage (mean \pm s.e.m.) of SOX2⁺/DAPI⁺ and of NeuN⁺/DAPI⁺ cells in the graft at the indicated grafting time point. *P* values were calculated using one-way ANOVA with post hoc Tukey's test between group comparisons ($F(2, 6) = 18.81$; $P = 0.0026$ for NeuN, $F(2, 6) = 24.3$; $P < 0.0001$ for SOX2), $n = 3$ independent animals per group. Asterisks indicate pair-wise comparisons with 14 dpi. **(c)** Comparative quantification of the percentage of SOX2⁺/DAPI⁺ and of NeuN⁺/DAPI⁺ cells in the graft compared with stage-matched organoids in culture at the indicated grafting or culture time point. Data are presented as mean \pm s.e.m., unpaired two-tailed *t*-test. For SOX2, 53 day vs. 14 dpi ($t = 3.059$, $df = 8$, $P = 0.0156$) and 102 d vs. 50 dpi ($t = 1.617$, $df = 9$, $P = 0.1369$, not significant). For NeuN, 53 d vs. 14 dpi ($t = 1.208$, $df = 8$, $P < 0.2617$, not significant) and 102 d vs. 50 dpi ($t = 12.15$, $df = 9$, $P < 0.0001$). Day 53 ($n = 7$ organoids), day 102 ($n = 8$ organoids) from three independent patches. $n = 3$ animals for 14 dpi and 50 dpi. **(d)** Immunofluorescence staining for GFP and human-specific GFAP (hGFAP) at the indicated time points showing astrocyte differentiation in the graft with increased abundance over time. Right panel is a higher magnification of the boxed area. **(e)** Immunostaining for oligodendrocyte marker Olig2 in the graft at 50 and 90 dpi. **(f)** Human graft contains Iba1⁺ microglia that do not co-localize with GFP. **(g)** Double immunofluorescence staining for presynaptic marker Synapsin (Syn) and the postsynaptic marker PSD95 at 50 dpi, showing a co-association between pre- and post-synaptic compartments and the formation of synaptic connections in the graft. The box indicates the region of magnification from the left panel; arrowheads indicate direct contact between a pre- and post-synapses puncta. Image shows a single plane confocal-Z-section. Nuclei were counterstained with DAPI. Scale bars: 100 μ m in **a**, 50 μ m in **d-f**, 5 μ m in **f** (right panel) and **g**. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.0001$. n.s., not significant.

Iba1⁺ cells were GFP negative, suggesting that they were of host origin, consistent with the lack of microglia cells in ungrafted organoids at least at day 38 of culture (Supplementary Fig. 3a).

Collectively, these results demonstrate that grafting of cerebral organoids supports progressive differentiation of neuronal and glial lineages and infiltration of brain immune cells into the graft.

Extensive axonal growth of engrafted organoids

We next investigated axonal outgrowth of cerebral organoids into the host brain. By 90 dpi, high levels of GFP⁺ axons were growing out of the graft sites, with axon density progressively diminishing

as a function of distance from the graft (Supplementary Fig. 4). Ventrally innervated bundles of human axons were detected in both hemispheres, with the ipsilateral hemisphere containing the highest number of fibers. Most axons grew out of organoids as a bundle through the cortical layers and the corpus callosum (Fig. 3a,b and Supplementary Fig. 4a,b). GFP⁺ human axons also traversed the amygdalar nucleus and the striatum. Human axons with lower fiber density were also observed ipsilaterally in the hippocampus, hypothalamus and thalamus, and in contralateral regions of the host brain. Notably, axonal growth was found not only in the grafted regions but also more rostrally (Supplementary Fig. 4a,b). These results




Figure 3 Organoid graft sends axonal projections with synaptic connectivity. **(a,b)** Confocal images of brain sections stained for GFP and obtained from ipsilateral **(a)** and contralateral cortex **(b)** of 90-dpi grafted mouse brain. Images show robust integration of GFP⁺ organoids and very large numbers of axons extending into the cortical regions and corpus callosum (CC) of the host brain. **(c)** Single focal plane confocal image of immunostaining for GFP, human-specific Synaptophysin (hSyn), and PSD95 in the host cortex at 90 dpi. Colocalization (arrowheads) and close association of hSyn and PSD95 indicate synaptic connectivity between the organoid axons and the host brain. Right panels show magnification of the boxed region in the left panel. **(d)** GFP signal with Z-stack 3D reconstruction of hSyn and colocalized only PSD95 puncta. **(e)** Quantification of the number of hSyn, PSD95, and hSyn/PSD95 colocalized puncta normalized to area and obtained from ipsilateral host cortical regions of 90-dpi grafted mouse brains. Data are presented as mean \pm s.e.m. $n = 3$ grafted animals. Nuclei were counterstained with DAPI. Scale bars: 50 μm in **a,b** and 5 μm in **c,d**.

demonstrate that grafted organoids can generate long-distance axonal projections to distant targets in the host brain.

Examination of synaptic connectivity between human axons and the host brain at 90 dpi showed a dense network of human presynaptic marker Synaptophysin (hSyn)-positive structures colocalized with GFP⁺ fibers in the host cortex (**Fig. 3c**), indicating maturation and, most likely, functionality of graft axons. Co-staining with PSD95, which recognizes human and mouse synapses, identified individual synapses between graft axons and the host brain (**Fig. 3c–e**), suggesting that human axons established synaptic connectivity with neurons in the host brain.

Vascularization and high viability of engrafted organoids

We next used a cranial glass window, which facilitated optical tracing of blood vessel growth, to test whether grafted organoids had a functional vascularization system (**Fig. 4a**). Blood vessels started to invade the graft area by 7–10 dpi and became extensively vascularized by 14 dpi (**Fig. 4b**), with successful vascularization occurring in $85.4\% \pm 6.4$ of grafted organoids (**Supplementary Fig. 5c**). Vascularization was essential for graft survival, as organoid implants that failed to vascularize displayed little or no fluorescent signal (data not shown). Immunostaining for the human and mouse endothelial cell markers Endoglin and CD31 demonstrated the growth of blood vessels in the grafts at 14 and 90 dpi, but not at 5 dpi, suggesting that organoid vascularization occurred between 5 and 14 dpi (**Fig. 4c** and **Supplementary Fig. 5a**). Moreover, CD31⁺ blood vessels did not coincide with staining for human-specific CD31, indicating that the vascular network in the grafts was derived from the host (**Supplementary Fig. 5b**). These results demonstrate growth of the vascular network in grafts and suggest that successful vascularization is essential for graft survival.

We next sought to understand how the *in vivo* brain environment and vascularization affected the growth and viability of organoids. Surface size tracing from day 0 to day 14 showed an overall reduction in graft size before vascularization, followed by a relative increase in the graft surface area that coincided with the timing of vascularization (**Supplementary Fig. 5d,e**). We compared cell death in the graft before and after vascularization to that of nearly stage-matched organoids cultured *in vitro*. In cultured organoids, apoptotic cell death was widespread at day 279 compared to day 31 (**Fig. 4d**). In contrast, grafts showed either limited or no detectable cell death at 14, 50, and 233 dpi *in vivo*. Notably, we observed low, yet variable, apoptotic signal in 31-d cultured organoids and at 5 dpi before overt vascularization occurred (two out of three of the grafts exhibited no detectable TUNEL, and one had a low TUNEL signal). These findings suggest that grafting and host-mediated vascularization promote viability of cerebral organoids that would otherwise display progressive cell death *in vitro*.

We studied whether implanted organoids could be imaged in awake grafted mice using *in vivo* two-photon scanning fluorescence microscopy. We imaged a clear GFP signal up to 500 μm in depth (**Supplementary Fig. 5f** and **Supplementary Video 1**). After infusing the grafted animal intravenously with a high-molecular-weight dextran dye, we imaged the graft under a two-photon microscope through a cranial window (**Fig. 4a**). Simultaneous live imaging of dextran and GFP showed blood vessel growth with active blood flow, demonstrating the development of functional vasculature networks inside the grafts (**Fig. 4e–g**, **Supplementary Fig. 5g** and **Supplementary Videos 2** and **3**).

Two-photon imaging of neuronal activity in engrafted organoids

We explored the functionality of grafted organoids by longitudinally measuring neuronal network activity *in vivo* using two-photon




Figure 4 Functional vasculature and decreased apoptosis in grafts. (a) Illustration of the imaging approach for live two-photon microscopy imaging of the organoid graft. (b) Serial macroscopic tracking of grafts showing dynamics of blood vessel perfusion by the recipient vascular system. Dotted area indicates the graft. (c) Grafts co-immunostained for the endothelial markers CD31 and hNuclei at the indicated time points. (d) Organoids have an elevated degree of cell death that is rescued after grafting. Top, TUNEL staining of grafted organoids and stage-matched cultured organoids at the indicated stage. Left panels show staining obtained from two different organoids and organoid grafts at day 31 and 5 dpi, respectively. Bottom, quantification of TUNEL⁺/DAPI⁺ cells in grafted organoids and nearly stage-matched cultured organoids of indicated ages. Values are represented as mean \pm s.e.m., ($n = 3$, except for 102-d organoid, $n = 4$, and 233 dpi $n = 2$); unpaired two-tailed *t*-test was used to compare mean difference between each group. Day 31 vs. 5 dpi ($t = 0.03656$, $df = 4$, $P = 0.9726$, not significant), day 53 vs. 14 dpi ($t = 14.67$, $df = 4$, $P = 0.0001$), day 102 vs. 50 dpi ($t = 5.943$, $df = 5$, $P = 0.0019$), and day 279 vs. 233 dpi ($t = 6.267$, $df = 3$, $P = 0.0082$). (e–g) *In vivo* two-photon imaging of blood vessels via dextran infusion as viewed through the cranial window. Organoids were implanted and TexasRed-dextran was injected at different time points of post-implantation (30 dpi in e, 120 dpi in f). (e) maximum projection of a 300- μ m stack taken in a 30-dpi graft (Supplementary Video 2). (f) top view of a three-dimensional reconstruction of a 500- μ m Z section in the organoids from a 120-dpi grafted animal (Supplementary Video 3). (g) Single z-plane obtained from 120-dpi graft and acquired at 141- μ m depth below the organoid surface, showing blood flow in the vasculature network (Supplementary Video 4). Nuclei were counterstained with DAPI. Scale bars: 1 mm in b, 50 μ m in c,d, and 100 μ m in e–g. ** $P < 0.01$, *** $P < 0.001$.




Figure 5 Two-photon imaging reveals neuronal activity in the graft. **(a)** illustration of our imaging system for Ca^{2+} imaging to monitor neuronal activity of the organoid graft using a two-photon microscope. **(b)** Representative images (from three frames) of two-photon Ca^{2+} imaging shown in grayscale (upper) and pseudo-color (lower). The images illustrate epochs of low (left and right panels) and high (middle) Ca^{2+} concentration in the graft during a Ca^{2+} transient at 78 dpi. The fluorescence intensity of the calcium sensor is markedly higher during periods of neuronal activity. Graph is a plot of full-frame average intensity during a Ca^{2+} transient, and red lines indicate time points corresponding to the frames in the left panels. **(c)** Typical field of view of neurons expressing jRGECO1a in the graft at 168 dpi. **(d)** Representative $\Delta F/F$ calcium traces of cells from the field of view depicted in **c**. Note the rhythmic and perfectly synchronized activity. **(e)** Representative $\Delta F/F$ traces from the same mouse at different time points after implantation. **(f)** The same cells in the graft can be imaged over different imaging sessions. $n = 3$ grafted animals in **b–e**, $n = 1$ grafted animal in **f**. Scale bar, 10 μm in **b,c**.

calcium imaging. Grafts displaying good GFP fluorescence were injected with an AAV8-CaMKII-jRGECO1a viral vector³⁶, which allows specific expression of a red fluorescent calcium sensor mainly in excitatory neurons (**Fig. 5a**). After allowing at least a 2-week period for protein expression, we acquired several recordings of calcium activity from awake animals (**Fig. 5b** and **Supplementary Videos 4–6**). Imaging data were analyzed by calculating relative changes in fluorescence ($\Delta F/F$) in regions of interest corresponding to neurons in the grafts. Grafted organoids had robust, recurrent, spontaneous rhythmic calcium transients interspersed with periods of no activity. The activity of the neuropil and cells was highly synchronized, and all identified cells in each field of view took part in every burst (**Fig. 5c,d**). We imaged engrafted animals at nearly 1-month intervals and were able to identify the same population of neurons over different imaging sessions. Spontaneous transient elevations of intracellular calcium were detected from the same regions and, in some cases, the same single neurons after more than 3 months of imaging (**Fig. 5e,f**). In summary, our *in vivo* two-photon calcium imaging demonstrated synchronized neural activity in the organoid grafted neurons.

Electrophysiological recording of neuronal activity in engrafted organoids

To determine whether organoid grafts exhibited electrophysiological activity, we conducted extracellular recording using multielectrode arrays³⁷ at various time points after grafting (**Fig. 6a–e** and **Supplementary Figs. 6** and **7**). For example, we successfully recorded action potentials (spikes) from two sites of the mid-stage 50-dpi-grafted organoids at different dorsal-ventral depths (DV) (**Supplementary Fig. 6a–c**) and from four sites of the late-stage 115-dpi graft (**Fig. 6d,e**). In contrast to the late-stage graft, which

displayed large numbers of isolated active neurons (three to eight neurons per recording site) at multiple depths, both low numbers of firing neurons (two to five neurons per recording site) and locations were observed in the mid-stage graft (**Fig. 6d,e** and **Supplementary Fig. 6a–c**). This observation indicates relatively advanced maturity at 115 dpi and is consistent with the temporal progressive neuronal maturation we observed in grafts (**Fig. 2**). Firing rates of these neurons gradually increased after removal of isoflurane anesthesia and sharply decreased with reintroduction, indicating suppression of neuronal activity by anesthesia. Thus, our data demonstrate neuronal activity and state-dependent firing changes of neurons in organoids that respond to external environmental stimuli.

To assess neuronal activity and interactions among neurons at the population level, we calculated the cross-correlation for neuron pairs in the same recording site. While neuron pairs in 50-dpi grafts showed little or no correlated activities, neuron pairs in 115-dpi organoids at depths of -1.5 mm and -2.0 mm showed strong correlation within ± 50 ms, suggesting synchronized firings of neurons in the late stage (**Fig. 6f** and **Supplementary Fig. 6c**). Overall, these results showed that late-stage grafts were accompanied by a more active and coordinated neuronal network than early-stage grafts, suggesting functional maturation at the late stage of grafted organoids.

Optogenetics revealed graft-to-host functional connectivity

To investigate functional connectivity between organoid neurons and the host brain, we established optogenetic control of grafts by injecting a *tdTomato*⁺ graft with AAV expressing Channelrhodopsin2-EYFP under the control of human synapsin promoter (AAV9-ChR2-eYFP). ChR2::YFP was expressed in both the grafts and their *tdTomato*⁺ axonal projections (**Supplementary Fig. 8a,b**). To functionally verify




Figure 6 *In vivo* electrophysiological recording in the graft. (a) Illustration of *in vivo* multielectrode array recording of the organoid graft. (b) Waveforms of action potentials (red) from neuron 3 shown in d,e, third row (DV –1.8 mm). (c) Principal component analysis (PCA) of waveforms from the same neuron in b. (d) Firing rate changes of single neurons (color-coded) obtained from a 115-dpi grafted organoid at four different DV depths (from top to bottom: –0.6 mm, –1.5 mm, –1.8 mm, and –2.0 mm) from the organoid surface. Each line (color-coded) indicates the firing rate of an individual neuron. Arrows on the top denote the time isoflurane was turned ON (filled arrows) and OFF (empty arrows). (e) Spike raster plots from the neurons in d at four different depths (from top to bottom: –0.6 mm, –1.5 mm, –1.8 mm, and –2.0 mm). Each vertical bar indicates a single spike. (f) Cross-correlation of neuron pairs shown in d. At depths of –1.5 mm and –2.0 mm, neuron pairs show strong correlated activity. $n = 3$ grafted animals.

ChR2 expression, we activated a ChR2-transduced graft, or uninjected negative control, while simultaneously recording its activity using *in vivo* extracellular recording. An electrode array bundled with optic fiber was implanted in the graft, and the graft was stimulated with blue laser while recording simultaneously. One sample neuron showed robust laser-evoked responses to three stimulation patterns as 1 s constant light, 50 Hz, and 20 Hz; no responses were observed in the uninjected control (**Supplementary Fig. 9a–d**). The response latency to laser onset was less than 5 ms and no significant response change was observed before or after the period of light illumination. These results indicated that graft neurons expressing ChR2 could be optogenetically activated by laser stimulation.

Next, we stimulated the ChR2-expressing graft while recording in host brain regions to search for potential neural activity changes in the host (**Supplementary Fig. 10**). We succeeded in recording local field potential (LFP) changes in host brain (fiber location: DV –1.7 mm; array location: AP –2.54 mm, ML –1.5 mm, DV –2.2 mm) (**Supplementary Fig. 10e–h**). In this example, the graft was activated with a 20-Hz stimulation pattern for 1 s, and laser onset was at 0 s. LFP signal from one electrode showed a negative peak right after laser onset (**Supplementary Fig. 10e**). The peak latency from laser onset was 20 ms (**Supplementary Fig. 10e**, inset). This peak was followed by 20-Hz oscillation lasting for 1 s (**Supplementary Fig. 10e,f**). These results showed that this host brain region received excitatory inputs

when stimulating the graft, which indicated functional connectivity from the graft to the host brain. Notably, another electrode in the same brain region detected a positive peak after laser onset, accompanied by a 20-Hz oscillation (**Supplementary Fig. 10g,h**). The response latency to laser onset was 20 ms (**Supplementary Fig. 10g**, inset). No responses were observed when recording from either a more dorsal position in the same animal or from a similar array position in the uninjected control (**Supplementary Fig. 10a–c, i–k**). This inhibition observed in the host brain region evoked by stimulation was likely caused by integration through the local neural network, which again strongly supports the existence of functional connectivity between the graft and the host. Taken together, these results demonstrate the utility of optogenetics in dissecting functional interaction between the organoid and the host brain and suggest functional integration of the organoids' neurons in host synaptic circuits.

In light of this finding of functional integration, we examined the behavior of grafted animals. We tested the spatial learning abilities of grafted mice and age-matched, NOD-SCID ungrafted controls using the Barnes maze. During training, no group differences were observed in the latency to locate the target location; nor was a group difference observed in the latency to locate the target during the probe test (**Supplementary Fig. 11a,b**). Analysis of errors made during training revealed that, although grafted mice made fewer errors on training day 1, this effect disappeared by day 2 (**Supplementary Fig. 11c**). However, the pattern of search errors during the probe trial did differ by group, with NOD-SCID controls searching primarily in the area adjacent to the target location whereas grafted mice showed little spatial preference for the target (**Supplementary Fig. 11d–f**). Together, these data suggest that both groups showed improvement with training, and no significant difference in learning ability was detected between grafted and ungrafted animals; however, mice with organoid implants did not perform as well as controls when tested for spatial memory, possibly due to the lesion made for organoid implants.

DISCUSSION

Brain organoids hold great potential for the investigation of aspects of human brain development and mental disorders. A limitation of organoid systems, however, is that they lack a vascular system and the complex physiological context of the intact human brain, such as, the interactions among cells, tissue, organ, and organism. In this study, we demonstrate that human brain organoids are amenable to transplantation in the rodent brain, showing integration, viability, long-term survival, vascularization, functional neuronal activity, and synaptic connectivity of the grafted organoid and the host. We also establish research tools that enable recording and optogenetic manipulation of neuronal activity with high spatial and temporal resolution within brain–organoid chimeras.

In the 1970s, transplantation of solid rodent tissue intracerebrally on a rich vascularized surface overlaying the anterior colliculus enabled a high degree of revascularization and survival of the implant^{21,31,32}. We adapted this classic knowledge for transplantation of brain organoids derived from hESCs. Our results show extensive infiltration of the host vasculature within a few days post-transplantation, with no sign of human endothelial cells in the graft (**Fig. 4** and **Supplementary Fig. 5a**). Although the majority of grafted organoids survived transplants that did not undergo vascularization failed to survive. Previous reports have demonstrated engraftment of several organoid systems in vasculature-rich areas such as the kidney capsule or colon^{23,24,26}; however, successful engraftment and maturation of human intestinal tissues required the presence of a mesenchymal

niche, and lack of a mesenchymal component resulted in failure of engraftment²⁴. Moreover, while liver organoids were transplanted in the brain with quite high success²⁵, co-culture with endothelial cells was required for vascularization and engraftment, highlighting the importance of the vascular bed. It is reasonable to assume that the survival of our organoid grafts was also promoted by adjacency to the brain ventricle, which allows circulation of cerebrospinal fluid through the graft cavity. We conclude that a vascular bed region in the brain aids successful engraftment of organoids, without the need for mesenchymal and endothelial cells.

Our data show that transplantation of cerebral organoids results in integration, progressive maturation and neuronal differentiation, synaptogenesis in the graft, and gliogenesis, thus sharing features with the dynamics of normal development and neurogenesis, and is consistent with organoids cultured *in vitro*. Transplanted embryonic neurons have been shown to integrate with great specificity into neocortical circuits in the adult brain³⁸. We observed human axonal growth to distant targets and various regions in the host brain, and evidence of functional synaptic connectivity between the graft and the host brain. Further research is needed to address questions about the specificity of the axonal projections and the precise synaptogenesis mapping.

Although they express mature markers and contain functional synapses, *in vitro* organoids generated with current systems appear to represent an embryonic developmental stage^{3,8,34}. Our Ca²⁺ imaging data demonstrated that the neurons in grafted organoids have synchronized activity, rather than sparse, isolated activity, suggesting an active neuronal network in the graft. Moreover, a study of the pattern of neuronal activity in mouse cortex showed that, as early as postnatal day 5, the activity was highly synchronous in local clusters of neurons³⁹. At the end of the second postnatal week, neocortical networks underwent a transition to a much more desynchronized state that lacked a clear spatial structure³⁹. Our observation of a similar pattern of Ca²⁺ imaging and neuronal activity in the grafted organoids suggests that, at least from a functional perspective, the organoids resemble late embryonic or early postnatal tissue. On the other hand, our extracellular multielectrode recordings, which have higher temporal resolution than Ca²⁺ imaging, indicated both higher numbers of active neurons and a partial switch from non-correlative to correlative neuronal activity during the course of transplantation, suggesting progressive neuronal maturation and generation of functional neuronal networks in the graft (**Fig. 6** and **Supplementary Fig. 6**). A recent study found a similar progressive functional maturation and emergence of a neuronal network in cultured cerebral organoids using extracellular multielectrode recording¹³. Determination of whether organoid transplantation enhances functional maturation of neural circuits compared to cultured organoids, and of the corresponding human development time point(s) of grafted organoids, requires further research. In addition, it would be interesting to test whether transplantation of other types of brain organoids, or further modifications, could promote full maturation.

We expect the experimental system presented here to serve as a useful tool for a number of biomedical applications. Transplantation has been used to study the survival, integration, axonal projection pattern, and synaptic connectivity of embryonic and hPSC-derived neurons cultured in two-dimensional (2D)^{38,40–44}, and to investigate the feasibility of using hPSC-derived neurons to treat central nervous system disorders^{1,45–50}. However, the inability of these 2D models to recapitulate the *in vivo*-like cytoarchitectural organization and synaptic connections of the brain has impeded their use in precise disease modeling or drug screening applications.

In contrast to neural 2D culture, cultured organoids recapitulate several key features of human brain organogenesis and cytoarchitecture, making them attractive models for studies of certain aspects of brain development and disease^{3,10,15,19,51}. However, *in vitro* studies are limited for investigating cell–tissue interactions, patterns of axonal projections, synaptic connectivity, and cross-interaction with the brain immune system. Transplantation of brain organoids could enable assessment of differentiation, axonal growth, and synaptic integration of neural organoids derived from patient-specific iPSCs under physiological conditions *in vivo*, facilitating mechanistic studies into the pathogenesis of neurodevelopmental, neuropsychiatric, and neurodegenerative disorders. Moreover, it could elucidate how neural progenitors and/or mature neural cells interact with their endogenous environments and vascular niches.

Preclinical animal models generally have a poor track record for accurately predicting which drugs will work in humans, as up to 80% of drugs that pass preclinical tests fail in humans^{52,53}. Our approach might be helpful for preclinical drug testing of patient-derived brain organoids under physiological conditions.

Finally, a wide variety of 3D organoid systems have been transplanted *in vivo*^{24–30,54,55}, in some cases to repair and rescue tissue damage^{23,25,55–57}, indicating that organoids may have potential for cell therapy. Our finding that human brain organoids can integrate and form functional circuits in the mouse brain suggests that organoids could provide an alternative to pure populations of a particular cell type, especially for the treatment of complex brain disorders or injuries. A central challenge will be to determine whether brain organoids can restore specific lost, degenerated, or damaged brain regions upon integration.

METHODS

Methods, including statements of data availability and any associated accession codes and references, are available in the [online version of the paper](#).

Note: Any Supplementary Information and Source Data files are available in the online version of the paper.

ACKNOWLEDGMENTS

We thank members of the Gage laboratory for helpful discussions; S. Schafer for the pCSC-CAG-GFP lentivirus and I. Verma for the pBOB-CAG-Td-Tomato construct. We also thank M. Shtrahman for assistance and two-photon imaging expertise, L. Moore, S. Bakta, S. Kim, B. Miller, C. Lim, and I. Guimont for their technical assistance, M.L. Gage for editorial comments, V. Mertens for illustrations, I. Farhy-Tselnick and J. Klug for technical advice, and M. Shtrahman, and T. Toda for critical reading and comments on the manuscripts. We thank U. Manor and the Waitt Advanced Biophotonics Core, K. Diffenderfer and the Salk Stem Cell Core, C. O'Connor and C. Fitzpatrick and the FACS Core, and the Salk Institute for generously providing critical infrastructural and financial support. We apologize to those whose work was not cited owing to space limitations. This work was supported by the NIH (U19 MH106434, U01 MH106882), The Paul G. Allen Family Foundation, Bob and Mary Jane Engman, The Leona M. and Harry B. Helmsley Charitable Trust Grant (2012-PG-MED), Annette C. Merle-Smith, The G. Harold and Leila Y. Mathers Foundation, JPB Foundation, Dolby Family Ventures for F.H.G. and NIH grants (R01NS083815, R01AG047669) for X.J. S.F. was funded by CIRM Bridges to Stem Cell Research Internship Program. A.A.M. received funding from the EMBO Postdoctoral Long-term Fellowship (ALTF 1214-2014, EMBO fellowship is co-funded also by the European Commission FP7-Marie Curie Actions, LTFCOFUND2013, GA-2013-609409), and is currently supported by the Human Frontiers Science Program (HFSP Long-Term Fellowship- LT001074/2015).

AUTHOR CONTRIBUTIONS

A.A.M. and F.H.G. conceived the idea for the project and wrote the manuscript. A.A.M. designed and performed the experiments and analyzed the data. A.A.M. generated hESC lines and organoids culture, performed cellular, molecular and histological assays and analyzed the data. S.F. and D.Q. performed cell

culture and histological experiments under the supervision of A.A.M. A.A.M., C.W.B., F.H.G., J.T.G., and S.J. performed surgeries. T.G. and C.W.B. performed two-photon imaging and analyzed the data. S.L.P. performed behavioral experiments. H.L. performed electrophysiological microelectrode and optogenetic experiments under the supervision of X.J. F.H.G. supervised the project and provided funding.

COMPETING INTERESTS

The author declares no competing interests.

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>. Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

1. Mertens, J., Marchetto, M.C., Bardy, C. & Gage, F.H. Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience. *Nat. Rev. Neurosci.* **17**, 424–437 (2016).
2. Shanks, N., Greek, R. & Greek, J. Are animal models predictive for humans? *Philos. Ethics Humanit. Med.* **4**, 2 (2009).
3. Kelava, I. & Lancaster, M.A. Dishing out mini-brains: current progress and future prospects in brain organoid research. *Dev. Biol.* **420**, 199–209 (2016).
4. Eiraku, M. *et al.* Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals. *Cell Stem Cell* **3**, 519–532 (2008).
5. Sasai, Y., Eiraku, M. & Suga, H. In vitro organogenesis in three dimensions: self-organising stem cells. *Development* **139**, 4111–4121 (2012).
6. Mariani, J. *et al.* Modeling human cortical development *in vitro* using induced pluripotent stem cells. *Proc. Natl. Acad. Sci. USA* **109**, 12770–12775 (2012).
7. Kadoshima, T. *et al.* Self-organization of axial polarity, inside-out layer pattern, and species-specific progenitor dynamics in human ES cell-derived neocortex. *Proc. Natl. Acad. Sci. USA* **110**, 20284–20289 (2013).
8. Lancaster, M.A. *et al.* Cerebral organoids model human brain development and microcephaly. *Nature* **501**, 373–379 (2013).
9. Pasca, A.M. *et al.* Functional cortical neurons and astrocytes from human pluripotent stem cells in 3D culture. *Nat. Methods* **12**, 671–678 (2015).
10. Qian, X. *et al.* Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure. *Cell* **165**, 1238–1254 (2016).
11. Jo, J. *et al.* Midbrain-like organoids from human pluripotent stem cells contain functional dopaminergic and neuromelanin-producing neurons. *Cell Stem Cell* **19**, 248–257 (2016).
12. Renner, M. *et al.* Self-organized developmental patterning and differentiation in cerebral organoids. *EMBO J.* **36**, 1316–1329 (2017).
13. Quadrato, G. *et al.* Cell diversity and network dynamics in photosensitive human brain organoids. *Nature* **545**, 48–53 (2017).
14. Mariani, J. *et al.* FOXG1-dependent dysregulation of GABA/glutamate neuron differentiation in autism spectrum disorders. *Cell* **162**, 375–390 (2015).
15. Bershteyn, M. *et al.* Human iPSC-derived cerebral organoids model cellular features of lissencephaly and reveal prolonged mitosis of outer radial glia. *Cell Stem Cell* **20**, 435–449.e4 (2017).
16. Iefremova, V. *et al.* An organoid-based model of cortical development identifies non-cell-autonomous defects in Wnt signaling contributing to Miller-Dieker syndrome. *Cell Rep.* **19**, 50–59 (2017).
17. Shen, Q. *et al.* Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. *Science* **304**, 1338–1340 (2004).
18. Yin, X. *et al.* Engineering stem cell organoids. *Cell Stem Cell* **18**, 25–38 (2016).
19. Giandomenico, S.L. & Lancaster, M.A. Probing human brain evolution and development in organoids. *Curr. Opin. Cell Biol.* **44**, 36–43 (2017).
20. Schwartz, M.P. *et al.* Human pluripotent stem cell-derived neural constructs for predicting neural toxicity. *Proc. Natl. Acad. Sci. USA* **112**, 12516–12521 (2015).
21. Stenevi, U., Björklund, A. & Svendgaard, N.A. Transplantation of central and peripheral monoamine neurons to the adult rat brain: techniques and conditions for survival. *Brain Res.* **114**, 1–20 (1976).
22. Gage, F.H. & Björklund, A. Intracerebral grafting of neuronal cell suspensions into the adult brain. *Cent. Nerv. Syst. Trauma* **1**, 47–56 (1984).
23. Yui, S. *et al.* Functional engraftment of colon epithelium expanded *in vitro* from a single adult Lgr5⁺ stem cell. *Nat. Med.* **18**, 618–623 (2012).
24. Watson, C.L. *et al.* An *in vivo* model of human small intestine using pluripotent stem cells. *Nat. Med.* **20**, 1310–1314 (2014).
25. Takebe, T. *et al.* Vascularized and functional human liver from an iPSC-derived organ bud transplant. *Nature* **499**, 481–484 (2013).
26. Clevers, H. Modeling development and disease with organoids. *Cell* **165**, 1586–1597 (2016).
27. Kretzschmar, K. & Clevers, H. Organoids: modeling development and the stem cell niche in a dish. *Dev. Cell* **38**, 590–600 (2016).
28. O'Rourke, K.P. *et al.* Transplantation of engineered organoids enables rapid generation of metastatic mouse models of colorectal cancer. *Nat. Biotechnol.* **35**, 577–582 (2017).
29. Roper, J. *et al.* In *vivo* genome editing and organoid transplantation models of colorectal cancer and metastasis. *Nat. Biotechnol.* **35**, 569–576 (2017).
30. Dye, B.R. *et al.* A bioengineered niche promotes *in vivo* engraftment and maturation of pluripotent stem cell derived human lung organoids. *eLife* **5**, e19732 (2016).

31. Gage, F.H. & Fisher, L.J. Intracerebral grafting: a tool for the neurobiologist. *Neuron* **6**, 1–12 (1991).
32. Gage, F.H., Björklund, A. & Stenevi, U. Denervation releases a neuronal survival factor in adult rat hippocampus. *Nature* **308**, 637–639 (1984).
33. Lancaster, M.A. & Knoblich, J.A. Generation of cerebral organoids from human pluripotent stem cells. *Nat. Protoc.* **9**, 2329–2340 (2014).
34. Camp, J.G. *et al.* Human cerebral organoids recapitulate gene expression programs of fetal neocortex development. *Proc. Natl. Acad. Sci. USA* **112**, 15672–15677 (2015).
35. Cahoy, J.D. *et al.* A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. *J. Neurosci.* **28**, 264–278 (2008).
36. Dana, H. *et al.* Sensitive red protein calcium indicators for imaging neural activity. *eLife* **5**, e12727 (2016).
37. Jin, X. & Costa, R.M. Start/stop signals emerge in nigrostriatal circuits during sequence learning. *Nature* **466**, 457–462 (2010).
38. Falkner, S. *et al.* Transplanted embryonic neurons integrate into adult neocortical circuits. *Nature* **539**, 248–253 (2016).
39. Golshani, P. *et al.* Internally mediated developmental desynchronization of neocortical network activity. *J. Neurosci.* **29**, 10890–10899 (2009).
40. Espuny-Camacho, I. *et al.* Pyramidal neurons derived from human pluripotent stem cells integrate efficiently into mouse brain circuits *in vivo*. *Neuron* **77**, 440–456 (2013).
41. Grealish, S. *et al.* Monosynaptic tracing using modified rabies virus reveals early and extensive circuit integration of human embryonic stem cell-derived neurons. *Stem Cell Rep.* **4**, 975–983 (2015).
42. Cunningham, M. *et al.* hPSC-derived maturing GABAergic interneurons ameliorate seizures and abnormal behavior in epileptic mice. *Cell Stem Cell* **15**, 559–573 (2014).
43. Qi, Y. *et al.* Combined small-molecule inhibition accelerates the derivation of functional cortical neurons from human pluripotent stem cells. *Nat. Biotechnol.* **35**, 154–163 (2017).
44. Thompson, L.H. & Björklund, A. Reconstruction of brain circuitry by neural transplants generated from pluripotent stem cells. *Neurobiol. Dis.* **79**, 28–40 (2015).
45. Kriks, S. *et al.* Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. *Nature* **480**, 547–551 (2011).
46. Bachoud-Lévi, A.C. & Perrier, A.L. Regenerative medicine in Huntington's disease: current status on fetal grafts and prospects for the use of pluripotent stem cell. *Rev. Neurol. (Paris)* **170**, 749–762 (2014).
47. Barker, R.A., Drouin-Ouellet, J. & Parmar, M. Cell-based therapies for Parkinson disease—past insights and future potential. *Nat. Rev. Neurol.* **11**, 492–503 (2015).
48. Lindvall, O. Clinical translation of stem cell transplantation in Parkinson's disease. *J. Intern. Med.* **279**, 30–40 (2016).
49. Steinbeck, J.A. & Studer, L. Moving stem cells to the clinic: potential and limitations for brain repair. *Neuron* **86**, 187–206 (2015).
50. Kikuchi, T. *et al.* Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model. *Nature* **548**, 592–596 (2017).
51. Di Lullo, E. & Kriegstein, A.R. The use of brain organoids to investigate neural development and disease. *Nat. Rev. Neurosci.* **18**, 573–584 (2017).
52. Perrin, S. Preclinical research: make mouse studies work. *Nature* **507**, 423–425 (2014).
53. Mak, I.W., Evaniew, N. & Ghert, M. Lost in translation: animal models and clinical trials in cancer treatment. *Am. J. Transl. Res.* **6**, 114–118 (2014).
54. Assawachananont, J. *et al.* Transplantation of embryonic and induced pluripotent stem cell-derived 3D retinal sheets into retinal degenerative mice. *Stem Cell Rep.* **2**, 662–674 (2014).
55. Huch, M. *et al.* Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis. *EMBO J.* **32**, 2708–2721 (2013).
56. Huch, M., Boj, S.F. & Clevers, H. Lgr5(+) liver stem cells, hepatic organoids and regenerative medicine. *Regen. Med.* **8**, 385–387 (2013).
57. Huch, M. *et al.* In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. *Nature* **494**, 247–250 (2013).

ONLINE METHODS

Animals All animal experiments described in this study were approved by the Institutional Animal Care and Use Committee (IACUC) at the Salk Institute for Biological Studies (12-00022), and the University of California San Diego (S12201), and were conducted in accordance with the National Institutes of Health's Guide for the Care and Use of Laboratory Animals. Male and female mice were group-housed when possible with up to five mice per cage, under standard conditions, and kept on a 12 h light/dark cycle (lights on at 6:00 a.m.) with *ad libitum* access to food and water. Immune-deficient NOD-SCID mice, aged 5–6 weeks, were purchased from Jackson Laboratories (JAX Stock: 001303) or were generated in our lab by breeding. In the majority of the experiments, female mice 6–10 weeks of age were used and the feasibility of the approach was validated in males.

Human embryonic stem cell culture. Human embryonic stem cells (hESCs) H9 (Wisconsin International Stem Cell (WISC) Bank, WiCell Research Institute, WA09 cells)⁵⁸ were cultured according to WiCell protocols (<http://www.wicell.org/home/support/stem-cell-protocols/stem-cell-protocols.cmsx>) on MEF feeders (Applied StemCell, Cat ASF-1114) in hESC medium containing DMEM/F12, 20% knockout serum replacement, 1% non-essential amino acids, 2 mM GlutaMAX, 0.1% (55 µM) 2-Mercaptoethanol (all from Invitrogen) and 10 ng/ml bFGF (Humanzyme), or on Matrigel (Corning, hESC-Qualified) in mTeSR1 (homemade by Salk STEM Core). Cultures were maintained in 6-well tissue culture plates and passaged at a ratio of 1:3 or 1:6 every 4–6 d by 1 mg/ml collagenase type IV (Invitrogen) for 30 min at 37 °C and mechanical scraping with a 5-ml glass pipette. All human pluripotent stem cells were maintained below passage 50 and confirmed negative for mycoplasma. Cells were confirmed to be karyotypically normal. All experiments involving cells from human subjects were performed in compliance with the institutional Embryonic Stem Cell Research Oversight (ESCRO) committee.

Generation of cerebral organoids. Cerebral organoids were generated and processed for analysis as described previously^{8,33} with minor modification. Briefly, hESCs were washed with Dulbecco's phosphate-buffered saline (D-PBS, Invitrogen) and dissociated with EDTA followed by Accutase to generate single cells. A total of 1×10^4 cells were then seeded into each well of an ultra-low-attachment 96-well plate (Nunc) to form single embryoid bodies (EBs) in medium containing DMEM/F12, 20% KSR, 3% FBS, 2 mM GlutaMAX, 1% non-essential amino acids, 50 nM b-mercaptoethanol and 4 ng/ml bFGF. ROCK inhibitor Y27632 (40 µM) was included for the first 24 h. EBs were maintained in 96-well plates for 2 d, and then the medium was changed to the same medium without FGF, and the cells were incubated for another 3–4 d. Medium then was changed to neural induction medium (NIM) consisting of DMEM/F12, 1× N2 supplement, 1% non-essential amino acids, 2 mM GlutaMAX and 1 µg/ml heparin (Sigma). On days 10–12, EBs were embedded in 30-µl droplets of Matrigel and were allowed to gel at 37 °C for 20–30 min. Embedded EBs were subsequently cultured in cerebral differentiation medium (CDM) consisting of 50% DMEM/F12, 50% Neurobasal, 0.5× N2 supplement, 1× B27 (without RA) supplement, 2 mM GlutaMAX, 2.8 ng/ml human insulin (Sigma), 0.5% non-essential amino acids, and 55 µM b-mercaptoethanol. Droplets were cultured in a stationary condition in 6-cm suspension culture dishes for 4 d, and then transferred to spinning flasks (Corning) containing culture with CDM +RA media. A total of ~40 organoids were added to each spinning flask, and medium was changed once every week or when the medium turned dark yellow, for the duration of the culture process. Matrigel was removed mechanically at day 20–22. For some experiments, an orbital shaker (65–80 r.p.m.) was used instead of the spinning flask. Only organoids that passed quality control—namely, clearing of embryoid body borders, formation of radially organized neuroepithelium before Matrigel embedding, and outgrowth and development of defined buds in Matrigel without massive cyst formation or premature differentiation—were selected for transplantation. In addition, organoids were examined by immunostaining to confirm the generation of polarized ventricle zone-like regions and dorsal forebrain identity in the organoids batch.

Immunofluorescence staining and histological processing. For organoids, residual Matrigel was manually removed from organoids and three washes were performed by placing organoids into mesh inserts in wells containing PBS. Organoids were then fixed in 4% PFA in 0.1 M phosphate buffer (PB, pH 7.2–7.5) with gentle shaking on ice, or at 4 °C, for 45–60 min; they were then washed three times in PBS and cryoprotected in 15% sucrose in PB for 4–5 h followed by 30% sucrose overnight at 4 °C. Three to five organoids then were embedded together in blocks in tissue-freezing medium (General Data), frozen on dry ice, and stored at –70 °C. 20-µm cryosections of organoids were obtained using a cryostat (Leica), mounted on Superfrost plus slides (Thermo Scientific, Menzel-Glaser), dried at room temperature (RT) for 30 min and stored up to 12 months at –70 °C. For each section set, every two sections were collected onto a slide to obtain a total of ten slides. This collection method was repeated with the same ten slides until 6–8 sections were mounted per slide and an entire serially sectioned collection set was obtained representing the whole organoid. Slides were dried for 30 min at RT and stored at –80 °C.

Immunofluorescence staining was performed as previously described⁵⁹. Slides were thawed, dried for 5–10 min in a 37 °C incubator, and rehydrated in PBS for 5 min, and blocked and permeabilized in blocking solution (5% normal donkey serum, 0.1% Triton X-100 in PBS). The tissue area and slide edges were outlined using a hydrophobic PAP pen, then slides were incubated with ~500 µl blocking/permeabilization solution (0.1% Triton-X, 5% normal donkey serum in PBS) in a humidified chamber for 1 h at RT. Slides were incubated in the appropriate primary antibody diluted in blocking solution under parafilm at 4 °C overnight. Sections were washed three times (5 min each) in PBT (0.05% Tween in PBS), incubated with appropriate fluorochrome-conjugated secondary antibodies diluted in blocking solution at RT for 1 h in the dark, washed twice in PBS, counterstained with DAPI (1 µg/ml, D9542; Sigma) for 5 min, rinsed twice in PBS and mounted with Shandon Immuno-Mount (Thermo Scientific, 9990412) ProLong gold for high-magnification imaging (Invitrogen, P36934). All images were collected on a Zeiss LSM880 confocal microscope and processed with Zen software, ImageJ software (NIH), and Adobe Photoshop CS4 (Adobe Systems, San Jose, CA). A list of the primary and secondary antibodies used in this study is provided as **Supplementary Table 1**. Some primary antibodies were used with two different dilutions for either tissue (T) or organoids (O). Cell death was detected using TUNEL assay (C10247, Invitrogen) following the manufacturer's protocol.

Mouse brain tissue collection. Mice were anesthetized with a lethal dose of ketamine and xylazine (130 mg/kg, 15 mg/kg; i.p.) and perfused transcardially with 0.9% NaCl or with 0.1 M PBS followed by fresh 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (pH 7.2–7.5). Brains were dissected and postfixed in 4% PFA overnight. Brains were cryoprotected for 72 h in 30% sucrose with 0.05% Na₃N at 4 °C. Brains were sectioned coronally on a cryostat at 20 µm thickness into 0.1 M PB and processed for immunostaining as described above.

Lentivirus production and generation of GFP hESCs. pCSC-CAG-GFP and pBOB-CAG-tdTomato were obtained from the lab of Indra Verma at the Salk Institute (Addgene 12337). VSVG-coated lentivirus particles were produced in HEK-293T cells. Briefly, HEK293 cells were transfected with a mixture of lentiviral construct and third-generation packaging plasmids using Polyethylenimine (PEI) (Cat 23966, Polysciences, Inc.). Culture medium was changed 4–5 h after and collected 72 h after transfection. Virus-containing medium was filtered through 0.45-µm filter concentrated via ultracentrifugation and stored at high concentration at –80 °C before usage.

To transduce hESCs with lentivirus, hESCs cultured on Matrigel were first dissociated using collagenase type IV and further dissociated by drawing small aggregates in and out of pipette briefly. hESCs were plated as small colonies onto Matrigel-coated dishes and fed mTeSR medium containing 10 µM ROCK inhibitor Y27632; the next day lentivirus particles were included in the media. When 80–90% confluence was reached, hESCs were subsequently FACS-sorted for GFP expression and replated at high density on Matrigel-coated dishes and fed mTeSR medium containing 10 µM ROCK inhibitor Y27632. Expression of lentiviral transgenes was evaluated using GFP fluorescence.

AAV viral injection to the organoid graft. AAV8-CaMKII-JRGECO1a³⁶ and AAV8-CaMKII-GCaMP6M (titer was 3.89×10^{12} GC/mL) were obtained from the Salk Virus Core. Mice were anesthetized with isoflurane (1–2% via a nose cone) and placed in a stereotaxic frame for virus injection. A ~0.5- to 1-mm hole was drilled through the cranial window and virus solution was delivered through stereotaxic surgery to the grafted organoids at three different Z locations using a microinjector (Nanoject II, Drummond Science). The mice were returned to their cages and allowed to recover. Mice were kept for at least 10 d before imaging.

Dextran injection. For dextran injection, Texas-Red 70,000 MW Dextran (D1830, Invitrogen) was diluted to 5% w/v (25 mg in 0.5 ml saline 0.9 NaCl). The mice were anesthetized and 50 μ l dextran was injected retro-orbitally using a 27-G needle. Mice were imaged immediately.

Surgical procedures: intracerebral implantation of cerebral organoids. Cerebral organoids were cultured for 40–50 d, or 31 d for 5- and 40-dpi experiments, before implantation. Only organoids that passed the quality control criteria mentioned above were selected. Mice were anesthetized with 5% (induction) and 1–2% (maintenance) isoflurane in oxygen. Dexamethazone (2.5 mg/kg) was injected subcutaneously to minimize edema. Each animal was fixed in a stereotaxic frame and body temperature was maintained at 37 °C using a water-circulation heating pad (Gaymar Industries). The skin above the skull was cut with a small incision. A ~3-mm diameter craniotomy was performed by drilling into the skull; the underlying dura mater was removed and a cavity was first made by aspiration with a blunt-tip needle attached to a vacuum line. The aspirative lesion was made unilaterally in the region of the retrosplenial cortex by removing the tissue overlying the anterior colliculus. The vascular bed of the choroidal fissure was exposed and the transplant was placed on the pial vessels overlying the collicles just caudal to the hippocampus. Sterile saline was used to irrigate the lesion and keep it free of blood throughout the surgery, and a piece of Gelfoam (Pfizer) was used to slow the bleeding and absorb the excess blood. The implanted organoid was then covered with a 5-mm cover slip to create a cranial window and was sealed with adhesive glue as described previously^{60,61}. The wound was closed with sutures or, alternatively, the implant was held in place with dental cement and a small titanium bar (9.5 × 3.1 × 1.3 mm) was attached to the skull to secure the animal to the microscope stage. Following completion of the surgery, carprofen (5 mg/kg, i.p., 100 μ l of 1 mg/ml) and buprenorphine (0.1 mg/kg, subcutaneous 100 μ l 0.01 mg/ml) were administered for inflammation and analgesic relief. The mice were then allowed to recover in a temperature-controlled cage and were returned to their home cages. Only brains with clearly identifiable GFP⁺ organoid grafts (indicating graft survival) were subsequently analyzed.

Two- photon imaging. Morphology and blood flow imaging were done under isoflurane anesthesia (1% isoflurane in O₂, vol/vol) and mice were head-fixed to the microscope stage via a titanium bar implant while resting on a 37 °C electrical heat blanket (Harvard Instrument). For imaging of Ca²⁺ activity, mice were head-fixed to the microscope using a custom-made titanium implant and allowed to run on a cylindrical treadmill⁶².

All *in vivo* imaging was done with a 2-photon laser scanning microscope (MOM, Sutter Instruments) using a femtosecond-pulsed laser (Chameleon Ultra II, Coherent) tuned to 910-nm or a 1,055-nm femtosecond-pulsed laser (Fidelity 2, Coherent) and a 16× water immersion objective (0.8 NA, Nikon). Images were acquired using the ScanImage software⁶³, which was written in MATLAB (MathWorks). Calcium imaged data were acquired at 3.9 Hz (512 × 128 pixels) and analyzed in MATLAB by extracting fluorescent intensity data from regions-of-interest corresponding to visualized cells expressing the calcium sensor, as previously described³⁹. Briefly, to correct for slight x-y drift, we aligned movies using a cross-correlation-based, subpixel image registration routine. Fluorescence traces were low-pass filtered and averaged to define a baseline level, and fluorescent changes normalized this baseline ($\Delta F/F$)³⁹. Time-stamping of movies, AVI file conversion, and color look-up table selection were done using ImageJ Plots of average full-frame intensity were done in Matlab.

In vivo electrophysiology. The *in vivo* neuronal recording procedure was performed as detailed before³⁷. Briefly, before recording, mice were lightly

anesthetized using isoflurane (4% induction; 1–2% sustained) and placed in a stereotaxic frame. For electrophysiological recording, we used electrode arrays (Innovative Neurophysiology Inc.) of 16 tungsten contacts (2 × 8), with each electrode being 35 μ m in diameter. Electrodes were spaced 150 μ m apart in the same row and 200 μ m apart between two rows. Total length of electrodes was 5 mm. The array was incrementally lowered into the organoid graft and silver grounding wire was attached to the scalp.

Neural activity was recorded using the MAP system (Plexon Inc., TX). The spike activities were initially sorted online with a build-in algorithm (Plexon Inc., TX). Only spikes with stereotypical waveforms clearly distinguished from noise and relatively high signal-to-noise ratio were tagged and saved for further analysis. After the recording session, the recorded spikes were further isolated into individual units by an offline sorting software (Offline Sorter, Plexon Inc.). Each individual unit displayed a clear refractory period in the inter-spike interval histogram, with no spikes during the refractory period (larger than 1.3 ms).

Spike sorting. Recording processing was performed as described previously^{37,64}. Briefly, the raw signals detected by a single electrode were first high-pass filtered with a cutoff of approximately 200–300 Hz, which yielded the continuous spike signal sampled at the same 40-kHz rate as the original signal using the OmniPlex Neural Data Acquisition System (Plexon Inc., TX). A sample section of the original signal is shown in Supplementary Figure 6f. Spikes with magnitude exceeding the threshold were tagged and recorded as waveforms (red arrows). Then we applied PCA analysis to these waveforms to discriminate the neuronal spikes from noise. On the PC plane, waveforms showing distinct shapes are classified into separate clusters.

Cross-correlation. The strength of correlated firings between neurons was estimated using a cross-correlation function⁶⁵. The cross-correlation function is defined as:

$$C_{IJ}(t_0) = \begin{cases} \frac{\sum_{t=0}^{T-|t_0|-1} I_t \cdot J_{t+t_0}}{R} & t_0 \geq 0 \\ C_{JI}(-t_0) & t_0 < 0 \end{cases}$$

$$R = \sqrt{\sum_{p=1}^T I_p^2 \cdot \sum_{q=1}^T J_q^2}$$

where I_t denotes the activity of neuron I at time t . J_{t+t_0} denotes the activity of neuron J at time $t + t_0$. $C_{IJ}(t_0)$ represents the correlation between neuron I and J at time lag t_0 . The temporal resolution of time lag was 1 ms. T is the total length of the spike train. In the calculation, the correlation strength was normalized against the firing rates of the neuron pair, which eliminated the influence of firing rate on correlation estimation.

Optogenetic stimulation. For optogenetic stimulation experiments, 1 μ l of concentrated AAV encoding Channelrhodopsin-2 (AAV9-ChR2-EYFP, titer 1.07×10^{13} GC/mL) was injected into the center of tdTomato-expressing organoid graft at 150 dpi. Two weeks later, the injected, and uninjected control, organoid graft was recorded using electrode arrays with an optic fiber directly attached. The fiber was ~200 μ m from the electrode tips and capable of delivering laser light. Uninjected or injected organoid graft were stimulated by 473-nm laser (5 mW, Laserglow Technologies) with three stimulation patterns as 1 s constant light, 50 Hz (50 pulses in 1 s) and 20 Hz (20 pulses in 1 s). The bundle of array and fiber was slowly lowered down into the organoid. The depth was adjusted within the range of 0 to –2.0 mm for the optimization of placement. For the local field potential (LFP) recordings, the array and the optic fiber were placed in the mouse brain region and in the organoid graft, respectively (fiber location: DV –1.7 mm; array location: AP –2.54 mm, ML –1.5 mm, DV –2.2 mm) and the same stimulation patterns were delivered. Note that in extracellular recording, the negative and positive voltage change represent excitation and inhibition, respectively. All experiments were performed while animals were under anesthesia.

Barnes maze. Organoid-implanted mice and age-matched NOD-SCID controls (~5-month-old animals; 100–116 dpi) were tested for spatial learning ability using the Barnes maze ($n = 7$ mice per group). The maze was 91 cm in diameter with 20 holes spaced evenly around the perimeter, one of which led into a darkened escape box. Prior to training, all mice completed a single habituation trial. Mice were placed in an opaque cylinder in the center of the maze for 30 s to disorient them to spatial cues in the room; then the cylinder was removed and mice were gently guided to the escape location, where they remained for 2 min to familiarize them with the escape box. For training, all mice received three trials per day for 3 d. Each trial consisted of 30 s in the disorientation cylinder, followed by 3 min of time to locate the escape box. Mice that did not successfully escape within the time limit were gently guided to the correct location. After escaping, mice were left in the escape box for 20 s. The maze surface and escape box were cleaned with Sani-Cloth wipes after each trial. A probe test was performed on day 4, 24 h after the final training day. The escape box was covered, and mice were allowed to explore the maze for 60 s for a single trial before being removed. The latency to locate the correct location was recorded during both training and probe phases. Errors (head dips or nose pokes above incorrect locations) were scored by a blinded observer from video recordings.

Quantification and statistical analysis. To determine the percentage of NeuN⁺ and SOX2⁺ cells in the organoid grafts, whole-brain sections of implanted brains stained with DAPI and the appropriate immunohistochemistry markers were imaged and used for quantification. The number of DAPI⁺ cells expressing various markers was manually counted using the “Cell Counter” plugin of Fiji. For each grafted brain, at least three regions of interest (ROI) were outlined using the “ROI tools.” The numbers of DAPI nuclei and cells expressing each marker from three sections and three grafting experiments per age group were included in the analysis. The cell counts from each grafted organoid were summed, and the percentage of DAPI⁺ cells expressing each marker was calculated. The percentage was averaged across three grafting experiments for each time point. Staining with DAPI and GFP was used to identify all cells and to determine the location of the graft. Moreover, human identity of the counted cells was confirmed by staining sequential sections with the hNuclei antibody.

Quantification of growth rate of the brain organoid after transplantation. Brain organoids were monitored from time 0 through day 13 or 14 under the stereomicroscope. Images were collected every day, and organoid surface areas were measured using Fiji. Normalized total organoid surface area (normalized to day 0, 100%) was calculated and averaged from at least three experiments (day 0–5 $n = 9$, day 6 $n = 8$, days 7 and 8 $n = 6$, day 9 $n = 5$, day 13 $n = 4$, day 14 $n = 3$).

Quantification of NeuN and SOX2 for comparison between grafted and ungrafted organoids (Fig. 2) was performed using automatic particle counting in Fiji, by first setting the threshold to obtain a binary image and remove background, then the tissue was traced in the DAPI channel and particles number were measured for all channels. Cell counts were measured and averaged relative to DAPI.

Quantification of vascularization success rate was performed by macroscopic monitoring of blood vessel outgrowth after 14 dpi. The success rate

was calculated by first averaging each experiment separately, and then average success rate from the ten independent experiments.

Barnes maze analysis. Mean latency and errors for each mouse were analyzed in GraphPad Prism 7. Training performance was analyzed by two-way ANOVA, with group as a between-subject factor and day as a within-subject factor. Sidak’s test was used post hoc for multiple comparisons. Latency to locate the target during the probe trial was analyzed by the Mann–Whitney test. Tests were two-tailed.

Statistics. Graphs and statistical analyses were generated using Prism 7 (GraphPad). For comparing multiple groups, a one-way ANOVA with post hoc Tukey’s test was used (Figs. 2d,e). Unpaired Student’s *t*-test (two-tailed) was used to compare two groups. Data are presented as a mean \pm s.e.m. (standard error of mean). Experiments were not randomized, and the investigator was not blinded. The experiments were repeated at least three times for each experiment, unless stated otherwise.

Ethics statement. All animal experiments described in this study were approved by the Institutional Animal Care and Use Committee (IACUC) at the Salk Institute for Biological Studies (12-00022), and the University of California San Diego (S12201), and were conducted in accordance with the National Institutes of Health’s Guide for the Care and Use of Laboratory Animals. All experiments involving cells from human subjects were performed in compliance with the institutional Embryonic Stem Cell Research Oversight committee (ESCRO).

Life Sciences Reporting Summary. Further information on experimental design is available in the Life Sciences Reporting Summary.

Data availability statement. The authors declare that the data that support the findings of this study are available from the corresponding author upon request.

58. Thomson, J.A. *et al.* Embryonic stem cell lines derived from human blastocysts. *Science* **282**, 1145–1147 (1998).
59. Mansour, A.A., Khazanov-Zisman, S., Netser, Y., Klar, A. & Ben-Arie, N. Noto3 plays an integral role in dorsoventral patterning of the spinal cord by segregating floor plate/p3 fates via Nkx2.2 suppression and Foxa2 maintenance. *Development* **141**, 574–584 (2014).
60. Gonçalves, J.T., Anstey, J.E., Golshani, P. & Portera-Cailliau, C. Circuit level defects in the developing neocortex of Fragile X mice. *Nat. Neurosci.* **16**, 903–909 (2013).
61. Gonçalves, J.T. *et al.* In vivo imaging of dendritic pruning in dentate granule cells. *Nat. Neurosci.* **19**, 788–791 (2016).
62. Heiney, S.A., Wohl, M.P., Chettih, S.N., Ruffolo, L.I. & Medina, J.F. Cerebellar-dependent expression of motor learning during eyelink conditioning in head-fixed mice. *J. Neurosci.* **34**, 14845–14853 (2014).
63. Pologruto, T.A., Sabatini, B.L. & Svoboda, K. ScanImage: flexible software for operating laser scanning microscopes. *Biomed. Eng. Online* **2**, 13 (2003).
64. Jin, X., Tecuapetla, F. & Costa, R.M. Basal ganglia subcircuits distinctively encode the parsing and concatenation of action sequences. *Nat. Neurosci.* **17**, 423–430 (2014).
65. Perkel, D.H., Gerstein, G.L. & Moore, G.P. Neuronal spike trains and stochastic point processes. II. Simultaneous spike trains. *Biophys. J.* **7**, 419–440 (1967).

Life Sciences Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.

For further information on the points included in this form, see [Reporting Life Sciences Research](#). For further information on Nature Research policies, including our [data availability policy](#), see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.

► Experimental design

1. Sample size

Describe how sample size was determined.

No statistical methods were used to predetermine the sample size. Sample sizes for experiments were estimated based on previous experience with a similar setup that showed significance. For experiments involving organoids culture, we used 3 independent cell cultures and each culture and each culture was considered as a biological replicate. Statistics were derived when at least 3 independent organoid cultures were analyzed. Experiments involved mice were performed once, while 2 or 3 animals where analyzed for each experiments/ time point. Each study was designed to use the minimum number of mice required to obtain informative results (that is, quantitative data amenable to statistical analysis).

2. Data exclusions

Describe any data exclusions.

Samples were excluded when there was no graft survival/GFP expression as detailed in the text and methods section, otherwise no samples were excluded.

3. Replication

Describe the measures taken to verify the reproducibility of the experimental findings.

Yes, all finding were reproducible.

4. Randomization

Describe how samples/organisms/participants were allocated into experimental groups.

Experiments of cultured organoids were not randomized, however animals were randomly assigned to different experimental groups and time points.

5. Blinding

Describe whether the investigators were blinded to group allocation during data collection and/or analysis.

Investigator was not blinded during organoid culture, grafting experiments, and data collections, however immunostaining and histological quantifications were performed by technicians who were blinded regarding the sample identity in most of cases.

Note: all *in vivo* studies must report how sample size was determined and whether blinding and randomization were used.

6. Statistical parameters

For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).

n/a Confirmed

- The exact sample size (*n*) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
- A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- A statement indicating how many times each experiment was replicated
- The statistical test(s) used and whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of any assumptions or corrections, such as an adjustment for multiple comparisons
- Test values indicating whether an effect is present
Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.
- A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
- Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)

See the web collection on [statistics for biologists](#) for further resources and guidance.

► Software

Policy information about [availability of computer code](#)

7. Software

Describe the software used to analyze the data in this study.

For image preparation and analysis: Fiji package of ImageJ V2.0.0-rc-64/1.51s and Adobe Photoshop CS6
For electrophysiology : offline sorting software 3.3.3 (Offline Sorter, Plexon Inc.) and Matlab R2013a
For two-photon microscopy: Images were acquired using the ScanImage software which was written in MATLAB R2016b (MathWorks)
For two-Photon imaging analysis : Fiji package of ImageJ V2.0.0-rc-64/1.51s
For statistical analysis: GraphPad Prism 7

For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). [Nature Methods guidance for providing algorithms and software for publication](#) provides further information on this topic.

► Materials and reagents

Policy information about [availability of materials](#)

8. Materials availability

Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a third party.

No unique materials were used, and all the materials employed are available from commercial sources.

9. Antibodies

Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).

The following primary and secondary antibodies were used for immunofluorescence: rabbit anti-GFP (1:1000, A6455; Invitrogen), chicken anti-GFP (1:1000, GFP-1020; Aves Lab), mouse anti-hNuclei (1:200, MAB1281; EMD Millipore), mouse anti-Mitochondria (1:1000, ab92824; Abcam), goat anti-SOX2 (1:250, sc-17320; Santa Cruz), rabbit anti-NeuN (1:1000, ab177487; Abcam), mouse anti-SMI 312 (1:1000, 837904; Biolegend), rabbit anti-Synapsin I (1:100, 574778; EMD Millipore), mouse anti-PSD95 (1:400, 75-028; Antibodies Inc.), chicken anti-MAP2 (1:500/1:1000, ab5392; Abcam) chicken anti-GFAP (1:2000, AB5541; EMD Millipore), mouse anti-hGFAP (1:500, 837201; Biolegend), rabbit anti-Iba1 (1:500/1:1000, 019-19741; Wako), rabbit anti-S100B (1:5000, Z0311, Dako), goat anti-Endoglin (1:100, BAF1320; R&D Systems), rat anti-CD31 (1:200, 102501; Biolegend), and mouse anti-hCD31 (1:200, 303101; Biolegend). Secondary antibodies conjugated with Alexa488, Cy3, Alexa647, or Rodamine Red-X (1:150) were from Jackson ImmunoResearch Laboratories.

Data also provided in the manuscript : In supplementary table 1, we have listed all the Antibodies used in this study and included the resource (i.e. company, catalog no...etc). Only commercially available, previously validated (see URLs in table 1), and routinely used antibodies have been used in this study. For each antibody, we provided clone number, provider and working dilution.

10. Eukaryotic cell lines

- State the source of each eukaryotic cell line used.
- Describe the method of cell line authentication used.
- Report whether the cell lines were tested for mycoplasma contamination.
- If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by [ICLAC](#), provide a scientific rationale for their use.

H9 hES cell line were obtained from WiCell Research Institute,

H9 hES cell line were obtained from WiCell Research Institute, and authenticated by WiCell.

All cell lined were confirmed to be mycoplasma free as stated in the methods section.

No commonly misidentified cell lines were used.

► Animals and human research participants

Policy information about [studies involving animals](#); when reporting animal research, follow the [ARRIVE guidelines](#)

11. Description of research animals

Provide all relevant details on animals and/or animal-derived materials used in the study.

Immune-deficient NOD-SCID mice, age 5–6 weeks, were purchased from Jackson Laboratories (JAX Stock#: 001303) or were generated in our lab by breeding. In the majority of the experiments, female mice 6–10 weeks of age were used and the feasibility of the approach was validated in males.

Policy information about [studies involving human research participants](#)

12. Description of human research participants

Describe the covariate-relevant population characteristics of the human research participants.

The study did not involve human research participants